

Special Issue

Gene- and Cell-Based Therapies for Retinal Diseases

Message from the Guest Editors

Vision loss due to inherited retinal dystrophies is a severe and mostly untreatable burden for 2–4 million patients worldwide. Thus, innovative strategies defeating neuronal dysfunction and cell loss are urgently needed. Gene- and cell-based therapies take center stage in the attempt to find effective ways to treat retinal diseases. In addition, interdisciplinary research approaches to identify factors influencing the outcome of those therapies such as inflammation and vector-related immune responses, and the development of robust and meaningful read-out parameters for upcoming clinical trials are needed. In this Special Issue, entitled "Gene- and Cell-Based Therapies for Retinal Diseases", we invite scientists to contribute original research or review articles to provide a comprehensive overview of current activities in this field of science and to highlight potential new areas of therapeutic development.

Guest Editors

Dr. Kerstin Nagel-Wolfrum

Institute of Molecular Physiology, Johannes Gutenberg University, 55099 Mainz, Germany

Dr. Knut Stieger

Department of Ophthalmology, Justus-Liebig-University Giessen, 35390 Giessen, Germany

Deadline for manuscript submissions

closed (30 November 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/113275

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).